851. Molecular Determination of High-Capacity Helper Dependent Adenoviral Vector Genomes In Vitro and In Vivo

Abstract

First generation (RAd) and high capacity (HC-Ad) adenoviral vectors are efficient delivery vehicles for transferring therapeutic transgenes in vivo into tissues/organs. The initial successes reported using adenoviral vectors in preclinical trials have been limited by immune related adverse side effects. This has been, in part, attributed to the use of poorly characterized preparations of adenoviral vectors and also to the untoward immune adverse side effects elicited when high doses of these vectors were used. HC-Ads have several advantages over RAds, including the lack of viral coding sequences, which after infection and uncoating, makes them invisible to the host's immune system. Another advantage is their large cloning capacity (up to |[sim]|35Kb). However, accurate characterization of HC- Ad vectors, and contaminating replication competent adenovirus (RCA) or helper virus is necessary before these preparations can be used safely in clinical trials. Consequently, the development of accurate, simple and reproducible methods to standardize and validate adenoviral preparations for the presence of contaminant genomes is required. Using a molecular method that allows accurate, reproducible and simultaneous determination of HC-Ad, contaminating helper virus and RCA genome copy numbers based on real time quantitative PCR (qPCR), we demonstrate accurate detection of these three genomic entities, within CsCl purified vector stocks, total DNA isolated from cells transduced in vitro, and from brain tissue infected in vivo. This approach will allow accurate assessment of the levels and biodistribution of HC-Ad and improve the safety and efficacy of clinical trials.